Effects of dietary factors on lipoprotein-associated phospholipase A 2 (Lp-PLA 2)

Current Atherosclerosis Reports

Volumn 13, Issue 6, 2011, Pages 461-466

  Wong, Cheuk Kit ^a   White, Harvey D ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Alcohol; BMI; Coronary events; Diet; Feeding; LP PLA 2; Monounsaturated fat; Protein; Statins; Triglycerides; Vascular events; Weight loss

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MONOUNSATURATED FATTY ACID; NICOTINIC ACID; PHYTOSTEROL; SIMVASTATIN; TETRAHYDROLIPSTATIN;

ALCOHOL CONSUMPTION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FAT INTAKE; HIGH RISK PATIENT; HUMAN; LIFESTYLE; PROTEIN EXPRESSION; PROTEIN INTAKE; RISK ASSESSMENT; THERAPY EFFECT; WEIGHT REDUCTION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ALCOHOL DRINKING; ATHEROSCLEROSIS; DIET; DIETARY FATS; DIETARY PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; WEIGHT LOSS;

EID: 81155152406     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-011-0201-4     Document Type: Article

References (25)

1. RA Stewart HD White 2011 The role of lipoprotein-associated phospholipase a(2) as a marker and potential therapeutic target in atherosclerosis Curr Atheroscler Rep 13 132 137 21207201 10.1007/s11883-010-0158-8 1:CAS:528:DC%2BC3MXjs1Cru74%3D
2. RS Rosenson 2010 Physiochemically modified apolipoprotein B-containing lipoproteins and the risk of cardiovascular disease J Intern Med 268 316 319 21050285 10.1111/j.1365-2796.2010.02272.x 1:CAS:528:DC%2BC3cXht12mtr7J
3. 2-mediated hydrolysis of oxidized LDL was highly associated with coronary artery endothelial dysfunction. (Pubitemid 46842787)
4. FD Kolodgie AP Burke KS Skorija, et al. 2006 Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis Arterioscler Thromb Vasc Biol 26 2523 2529 16960105 10.1161/01.ATV.0000244681.72738.bc 1:CAS:528:DC%2BD28XhtVyitbjN (Pubitemid 44607475)
5. D Mannheim J Herrmann D Versari, et al. 2008 Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques Stroke 39 1448 1455 18356547 10.1161/STROKEAHA.107.503193 1:CAS:528:DC%2BD1cXkvVeitr0%3D
6. 2 and vascular disease, including stroke.
7. M Persson JA Nilsson JJ Nelson B Hedblad G Berglund 2007 The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort Atherosclerosis 190 388 396 16530769 10.1016/j.atherosclerosis.2006.02.016 1:CAS:528:DC%2BD2sXls1KmsA%3D%3D This is a large epidemiologic study in a healthy population. (Pubitemid 46074030)
8. 2 and coronary disease.
9. Heart Protection Study Collaborative Group 2010 Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality J Intern Med 268 348 358 10.1111/j.1365-2796.2010.02258.x This study analyzed apoB in the outcome model.
10. 2.
11. MH Davidson MA Corson MJ Alberts, et al. 2008 Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines Am J Cardiol 101 51F 57F 18549872 10.1016/j.amjcard.2008.04.019 1:CAS:528:DC%2BD1cXosVantr0%3D
12. VG Saougos AP Tambaki M Kalogirou, et al. 2007 Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2 Arterioscler Thromb Vasc Biol 27 2236 2243 17656665 10.1161/ATVBAHA.107.147280 1:CAS:528:DC%2BD2sXhtVKhsrbF (Pubitemid 350287255)
13. JB Muhlestein HT May JR Jensen, et al. 2006 The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study J Am Coll Cardiol 48 396 401 16843192 10.1016/j.jacc.2006.05.009 1:CAS:528:DC%2BD28XmvValtLg%3D
14. 2 values were 62% higher (P < 0.0001) in the fed state in patients compared with controls. (Pubitemid 40544302)
15. JT Kuvin DM Dave KA Sliney, et al. 2006 Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease Am J Cardiol 98 743 745 16950175 10.1016/j.amjcard.2006.04.011 1:CAS:528:DC%2BD28Xptlyrsro%3D (Pubitemid 44301006)
16. TD Filippatos IF Gazi EN Liberopoulos, et al. 2007 The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome Atherosclerosis 193 428 437 16911813 10.1016/j.atherosclerosis.2006.07. 010 1:CAS:528:DC%2BD2sXotVClsbk%3D (Pubitemid 47058108)
17. HD White 2010 Darapladib and its potential for plaque stabilization and prevention of cardiac events Clinical Lipidology 5 465 476 10.2217/clp.10.45 1:CAS:528:DC%2BC3cXpvFKgt70%3D
18. O'Donoghue ML, Braunwald E, White HD, Serruys P, et al. Study design and rationale for the SOLID-TIMI 52 (Stabilization Of pLaques usIng Darapladib - Thrombolysis in Myocardial Infarction) Trial in patients after an acute coronary syndrome. Am Heart J. 2011;in press.
19. 2.
20. BM Wolfe PM Giovannetti 1991 Short-term effects of substituting protein for carbohydrate in the diets of moderately hypercholesterolemic human subjects Metabolism 40 338 343 2011075 10.1016/0026-0495(91)90142-J 1:STN:280: DyaK3M7os1yguw%3D%3D
21. EA Brinton 2010 Effects of ethanol intake on lipoproteins and atherosclerosis Curr Opin Lipidol 21 346 351 20616714 10.1097/MOL. 0b013e32833c1f41 1:CAS:528:DC%2BC3cXovV2ltr0%3D
22. T Tzotzas TD Filippatos A Triantos E Bruckert AD Tselepis DN Kiortsis 2008 Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women Nutr Metab Cardiovasc Dis 18 477 482 17928209 10.1016/j.numecd.2007.04.004 1:CAS:528:DC%2BD1cXht1aqt7rN
23. LT Braun MH Davidson 2010 Lp-PLA2: A new target for statin therapy Curr Atheroscler Rep 12 29 33 20425268 10.1007/s11883-009-0074-y 1:CAS:528: DC%2BC3cXht1Cjs7jL
24. MW Pedersen W Koenig JH Christensen EB Schmidt 2009 The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults Eur J Nutr 48 1 5 19030909 10.1007/s00394-008-0758-z
25. DH Kim SJ Jung IS Chung, et al. 2005 Ergosterol peroxide from flowers of Erigeron annuus L. as an anti-atherosclerosis agent Arch Pharm Res 28 541 545 15974439 10.1007/BF02977755 1:CAS:528:DC%2BD2MXltVamtL8%3D